- Home
- TALK vs IMAB Comparison
TALK vs IMAB Comparison
Compare TALK & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TALK
- IMAB
- Stock Information
- Founded
- TALK 2012
- IMAB 2014
- Country
- TALK United States
- IMAB United States
- Employees
- TALK N/A
- IMAB 32
- Industry
- TALK Medical/Nursing Services
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- TALK Health Care
- IMAB Health Care
- Exchange
- TALK Nasdaq
- IMAB Nasdaq
- Market Cap
- TALK 435.4M
- IMAB 384.6M
- IPO Year
- TALK N/A
- IMAB 2020
- Fundamental
- Price
- TALK $2.80
- IMAB $5.09
- Analyst Decision
- TALK Buy
- IMAB Strong Buy
- Analyst Count
- TALK 6
- IMAB 4
- Target Price
- TALK $4.50
- IMAB $6.75
- AVG Volume (30 Days)
- TALK 1.6M
- IMAB 4.7M
- Earning Date
- TALK 08-05-2025
- IMAB 08-20-2025
- Dividend Yield
- TALK N/A
- IMAB N/A
- EPS Growth
- TALK N/A
- IMAB N/A
- EPS
- TALK 0.02
- IMAB N/A
- Revenue
- TALK $202,611,000.00
- IMAB N/A
- Revenue This Year
- TALK $21.98
- IMAB N/A
- Revenue Next Year
- TALK $20.60
- IMAB N/A
- P/E Ratio
- TALK $165.52
- IMAB N/A
- Revenue Growth
- TALK 17.43
- IMAB N/A
- 52 Week Low
- TALK $1.70
- IMAB $0.60
- 52 Week High
- TALK $4.36
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- TALK 63.99
- IMAB 68.67
- Support Level
- TALK $2.53
- IMAB $4.13
- Resistance Level
- TALK $2.53
- IMAB $5.90
- Average True Range (ATR)
- TALK 0.12
- IMAB 0.66
- MACD
- TALK 0.04
- IMAB 0.09
- Stochastic Oscillator
- TALK 95.87
- IMAB 72.73
About TALK Talkspace Inc.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).